Join to access to all OVN content. Join for Free
An Unexpected Journey From Novice MSL to Global Medical Excellence Leader with Tonya Johnson
Medical Science Liaison networking and mentorship Key Opinion Leader relationships career development strategies emotional intelligence for MSLs

An Unexpected Journey From Novice MSL to Global Medical Excellence Leader with Tonya Johnson


Share This Article


Summary

In this episode, Tom Caravela welcomes Dr. Tanya Johnson, who shares her inspiring journey from Newark to becoming a Medical Science Liaison (MSL). Tanya emphasizes the importance of networking and mentorship in the MSL field and offers insights into building and maintaining strong Key Opinion Leader (KOL) relationships. She discusses career development strategies, the roles of mentors and sponsors, and proactive career management. Tanya also explores the global medical excellence leader role and highlights key skills and emotional intelligence necessary for MSLs today. The episode concludes with Tanya's thoughts on future directions for MSLs.

My guest today is Dr. Tonya Johnson, she was a former Global Medical leader of MSL Excellence. We discuss TJ’s trek from no experience to Global Medical Affairs leader.

In this episode we discuss:

  • Who is Tonya
  • Transitioning to the industry
  • The concept of mentors and sponsors
  • The approach to finding a mentor or a sponsor
  • Finding mentors
  • What is Global Medical Excellence
  • What skills are mandatory for the MSLs of today

Click for Source
Medical Science Liaison, networking and mentorship, Key Opinion Leader relationships, career development strategies, emotional intelligence for MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN